Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Polycystic Kidney, Autosomal Dominant | 3 | 2018 | 31 | 1.63 | Why? |
| Antidiuretic Hormone Receptor Antagonists | 1 | 2018 | 18 | 0.76 | Why? |
| Peritoneal Dialysis | 1 | 2020 | 498 | 0.55 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 94 | 0.46 | Why? |
| Glomerulonephritis | 1 | 2012 | 226 | 0.38 | Why? |
| Renal Dialysis | 4 | 2021 | 4358 | 0.35 | Why? |
| Kidney Failure, Chronic | 2 | 2020 | 3222 | 0.33 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.25 | Why? |
| Acid-Base Imbalance | 1 | 2021 | 46 | 0.22 | Why? |
| Nephritis, Interstitial | 1 | 2020 | 83 | 0.19 | Why? |
| Hypokalemia | 1 | 2021 | 195 | 0.18 | Why? |
| Hemodialysis Units, Hospital | 1 | 2020 | 195 | 0.18 | Why? |
| Symptom Flare Up | 1 | 2020 | 432 | 0.16 | Why? |
| Cysts | 1 | 2017 | 94 | 0.15 | Why? |
| Immunologic Factors | 1 | 2012 | 4206 | 0.15 | Why? |
| Imaging, Three-Dimensional | 1 | 2017 | 680 | 0.11 | Why? |
| Glomerulonephritis, Membranous | 1 | 2012 | 71 | 0.11 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.11 | Why? |
| Lupus Nephritis | 1 | 2012 | 113 | 0.11 | Why? |
| Nephrosis, Lipoid | 1 | 2012 | 99 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.11 | Why? |
| Cryoglobulinemia | 1 | 2012 | 144 | 0.10 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.10 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2012 | 235 | 0.09 | Why? |
| Image Processing, Computer-Assisted | 1 | 2017 | 1383 | 0.09 | Why? |
| Hemorheology | 1 | 2007 | 17 | 0.09 | Why? |
| Kidney Transplantation | 2 | 2020 | 5397 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.08 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Rituximab | 1 | 2012 | 1096 | 0.07 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Aged | 10 | 2021 | 215776 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.05 | Why? |
| Europe | 1 | 2018 | 12702 | 0.05 | Why? |
| Enzyme Induction | 1 | 2020 | 89 | 0.05 | Why? |
| Hematologic Diseases | 1 | 2007 | 614 | 0.05 | Why? |
| Plasma Exchange | 1 | 2007 | 763 | 0.05 | Why? |
| Hematuria | 1 | 2021 | 284 | 0.05 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.05 | Why? |
| Diuretics | 1 | 2021 | 326 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Angiotensin I | 1 | 2020 | 200 | 0.04 | Why? |
| Potassium | 1 | 2021 | 325 | 0.04 | Why? |
| Proteinuria | 1 | 2021 | 474 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Humans | 14 | 2021 | 930598 | 0.04 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Organ Specificity | 1 | 2020 | 1070 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.03 | Why? |
| Angiotensin II | 1 | 2020 | 601 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Down-Regulation | 1 | 2020 | 1416 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Clinical Trials as Topic | 1 | 2012 | 7330 | 0.03 | Why? |
| Frail Elderly | 1 | 2021 | 1427 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.03 | Why? |
| Female | 7 | 2021 | 380317 | 0.03 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Italy | 2 | 2021 | 38444 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Blood Viscosity | 1 | 2007 | 71 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.02 | Why? |
| Blood Proteins | 1 | 2007 | 551 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Adult | 3 | 2021 | 244371 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Guidelines as Topic | 1 | 2007 | 2844 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Algorithms | 1 | 2007 | 7346 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |